Business
Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans
About this update from Avalon Globocare Corp.
[{"type":"text","content":"Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans to apply for additional patents related to QTY code applications jointly with MIT FREEHOLD, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new publication featuring the Company’s QTY protein code technology in Chemical Reviews, a top-ranked peer-reviewed scientific journal and the official journal of American Chemical Society (journal Impact Factor is 72). The publication, entitled “Protein Design: From the Aspect of Water Solubility and Stability,” focuses on the innovative QTY protein design code—co-developed by Avalon—as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications. The Company initially licensed the technology from the Massachusetts Institute of Technology (MIT) and has advanced the platform through a sponsored research agreement with the university. The “QTY Code” breakthrough technology, developed in 2011 by the laboratory of Dr. Shuguang Zhang, Ph.D., of MIT’s Media lab in Boston, MA, is a protein-design platform that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development. The publication provides a comprehensive review of the QTY protein code design platform. Proteins are molecular machines inside of cells that perform the majority of essential biological functions. Proteins need to maintain their correct 3-dimensional structure for human health, to perform their functions. Well-known human disorders are related to mis-folding of proteins that result in their poor solubility, stability, and function. A better understanding of the protein folding process is necessary for development of therapies for diseases involving protein misfolding. The QTY code design approach may have the potential to facilitate the 1) development of important drug modalities including monoclonal antibodies, 2) creation of water-soluble proteins from insoluble proteins that are important but difficult to work with drug targets, 3) evolution of computational methods for r...